Pasha, Nida http://orcid.org/0000-0002-2412-2112
Turner, Nicholas C.
Article History
Received: 28 August 2020
Accepted: 2 June 2021
First Online: 19 July 2021
Competing interests
: N.C.T. has received advisory board honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, GlaxoSmithKline, Zentalis pharmaceuticals, Repare Therapeutics and Arvinas and research funding from AstraZeneca, BioRad, Pfizer, Roche/Genentech, Merck, Sharpe and Dohme, and Guardant Health.